Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05758493 · ClinicalTrials.gov registry record · Phase 2
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
A Phase 2 study of Amyloidosis and Transthyretin Amyloidosis, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT05758493 is a Phase 2 study of Amyloidosis and Transthyretin Amyloidosis that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 150 participants, below the 1,123-participant average among 28 other Amyloidosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05758493, a Phase 2 study of Amyloidosis and Transthyretin Amyloidosis, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1)identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 2) Correlate the uptake with the structure and function of different organs, including the heart. To achieve these goals, eligible patients will undergo primarily hybrid positron emission tomography and magnetic resonance imaging (PET/MRI). In a subgroup of patients who are unable to undergo PET/MR, computed tomography will be used instead of MRI (i.e. PET/CT). In a subgroup of patients, repeat imaging with the same modality will be done at a interval of 6-12 months. Clinically available data (demographics, phenotype, imaging, laboratory) will also be collected to characterize the disease in each patient.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 124I-Evuzamitide
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2028-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05758493
The ClinicalTrials.gov registry entry for NCT05758493 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,123-participant average among 28 other Amyloidosis trials with a reported enrollment target (87% lower). The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 124I-Evuzamitide is the first listed.
NCT05758493 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT05758493 about?
NCT05758493 is a clinical study titled "Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis". This is a single center prospective study evaluating 124I-evuzumitide in patients with systemic amyloidosis. The purpose of this study is to 1)identify and characterize the distribution and uptake of 124I-evuzumitide in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and 2) Correlate th...
What is the current status of trial NCT05758493?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-01-10. Estimated completion is 2028-03-10.
What conditions does trial NCT05758493 study?
This clinical trial studies the following conditions: Amyloidosis, Transthyretin Amyloidosis.
What interventions are being tested in trial NCT05758493?
The interventions under investigation include: 124I-Evuzamitide (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05758493?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05758493 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
COMPLETED · Phase 2
-
Ixazomib Rollover Study
COMPLETED · Phase 2
-
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.